patent_istock-643607264_warchi-
warchi / iStockphoto.com
14 June 2018PharmaEllen Sherin

Investing in patent search: tips for practitioners

What is the cost of a single missed reference in the IP world? It depends on the situation. Research programmes that spend millions to develop inventions which turn out to be unpatentable because of prior art, long drawn-out prosecutions with multiple rejections, post-grant invalidities and infringement litigation are just some of the possibilities. No search is perfect, and there is always the chance of missing something—but the better the search, the better the subsequent decision-making.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
9 July 2026   Separate lawsuits target Indian and Taiwanese pharma companies as Exelixis seeks to keep rival cabozantinib products off the US market until key patents expire.
Pharma
7 July 2026   Leading women from the pharmaceutical and biotechnology sectors are among the more than 100 professionals recognised in a newly released Influential Women in IP 2026 list, which celebrates leadership, expertise and innovation.
Pharma
1 July 2026   Otsuka v Sun Pharma could redefine which pharmaceutical patents qualify for patent term extensions, with major implications for innovator companies, generic manufacturers and the future of market exclusivity in the country.